Enrolling Studies
- A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer’s Disease
- Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer’s Disease Dementia (SERENADA)
- A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
- A Study of Remternetug (LY3372993) in Early Alzheimer’s Disease (TRAILRUNNER-ALZ 3)
- Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-REAL US)
- A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer’s Disease
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab (FILIOS)
- Study to Evaluate the Maintenance of Efficacy When Transitioning From Anti-CD20 Therapy to Ublituximab (ENHANCE)
- MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® (MS-DETECT)
- A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson’s Disease (PD) Participants With Motor Fluctuations
- A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of TB006 in Participants With Parkinson’s Disease
- An interventional efficacy and safety, phase 3, double-blind, randomized, 2-arm study to investigate the prevention of chronic migraine with rimegepant compared with placebo in participants 18 years of age or older
- A phase 4, single-arm, open-label study to evaluate the safety, tolerability and effectiveness of redosing of rimegepant in participants 18 years of age or older for the acute treatment of migraine